Drug
HRS-5041
HRS-5041 is a pharmaceutical drug with 3 clinical trials. Currently 2 active trials ongoing.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
2(67%)
Phase Distribution
Ph phase_1
2
67%
Ph phase_2
1
33%
Phase Distribution
2
Early Stage
1
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
2(66.7%)
Phase 2Efficacy & side effects
1(33.3%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
2
trials recruiting
Total Trials
3
all time
Status Distribution
Active(3)
Detailed Status
Recruiting2
Not yet recruiting1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
2
Success Rate
N/A
Most Advanced
Phase 2
Trials by Phase
Phase 12 (66.7%)
Phase 21 (33.3%)
Trials by Status
not_yet_recruiting133%
recruiting267%
Recent Activity
2 active trials
Showing 3 of 3
recruitingphase_1
Phase Ib Study of HS-20093+HRS-5041 in Patients With Advanced Prostate Cancer
NCT07115446
recruitingphase_1
Study of HRS-5041 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
NCT05942001
not_yet_recruitingphase_2
Study of HRS-2189 Combined HRS-5041 in Prostate Cancer
NCT06738745
Clinical Trials (3)
Showing 3 of 3 trials
NCT07115446Phase 1
Phase Ib Study of HS-20093+HRS-5041 in Patients With Advanced Prostate Cancer
NCT05942001Phase 1
Study of HRS-5041 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
NCT06738745Phase 2
Study of HRS-2189 Combined HRS-5041 in Prostate Cancer
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3